Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,8500918,tmax,"In a supine position, the gastrointestinal absorption rate of flunitrazepam (tmax 0.6 h) was faster than that of midazolam (tmax 0.95 h).",Midazolam and flunitrazepam: pharmacokinetics and effects on night time respiration and body movements in the elderly. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8500918/),h,0.6,1771,DB01544,Flunitrazepam
,8500918,tmax,"In a supine position, the gastrointestinal absorption rate of flunitrazepam (tmax 0.6 h) was faster than that of midazolam (tmax 0.95 h).",Midazolam and flunitrazepam: pharmacokinetics and effects on night time respiration and body movements in the elderly. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8500918/),h,0.95,1772,DB01544,Flunitrazepam
,6123121,sensitivity,The sensitivity limits are 0.5 ng/ml for flunitrazepam and 1-2 ng/ml for desmethylflunitrazepam.,Automated electron-capture gas chromatographic analysis of flunitrazepam in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6123121/),[ng] / [ml],0.5,3164,DB01544,Flunitrazepam
,6123121,sensitivity,The sensitivity limits are 0.5 ng/ml for flunitrazepam and 1-2 ng/ml for desmethylflunitrazepam.,Automated electron-capture gas chromatographic analysis of flunitrazepam in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6123121/),[ng] / [ml],1-2,3165,DB01544,Flunitrazepam
,8275648,Bioavailability,Bioavailability is 67% after oral doses of 5-20 mg.,Zolpidem: a nonbenzodiazepine hypnotic for treatment of insomnia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8275648/),%,67,25177,DB01544,Flunitrazepam
,15203048,limit of quantification,The limit of quantification was 0.025 ng/microl plasma for 7-AFNZ and 0.125 ng/microl for the four other compounds.,"Development and validation of a gas chromatography-mass spectrometry method for the simultaneous determination of buprenorphine, flunitrazepam and their metabolites in rat plasma: application to the pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15203048/),[ng] / [plasma·μl],0.025,27615,DB01544,Flunitrazepam
,15203048,limit of quantification,The limit of quantification was 0.025 ng/microl plasma for 7-AFNZ and 0.125 ng/microl for the four other compounds.,"Development and validation of a gas chromatography-mass spectrometry method for the simultaneous determination of buprenorphine, flunitrazepam and their metabolites in rat plasma: application to the pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15203048/),[ng] / [μl],0.125,27616,DB01544,Flunitrazepam
,15203048,Recoveries,"Recoveries were 71, 67 and 81%, for BUP, FNZ and N-DMFNZ, respectively, and 51% for NBUP and 7-AFNZ, with CV ranging from 5.4 to 13.9%, and were concentration-independent.","Development and validation of a gas chromatography-mass spectrometry method for the simultaneous determination of buprenorphine, flunitrazepam and their metabolites in rat plasma: application to the pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15203048/),%,71,27617,DB01544,Flunitrazepam
,15203048,Recoveries,"Recoveries were 71, 67 and 81%, for BUP, FNZ and N-DMFNZ, respectively, and 51% for NBUP and 7-AFNZ, with CV ranging from 5.4 to 13.9%, and were concentration-independent.","Development and validation of a gas chromatography-mass spectrometry method for the simultaneous determination of buprenorphine, flunitrazepam and their metabolites in rat plasma: application to the pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15203048/),%,67,27618,DB01544,Flunitrazepam
,15203048,Recoveries,"Recoveries were 71, 67 and 81%, for BUP, FNZ and N-DMFNZ, respectively, and 51% for NBUP and 7-AFNZ, with CV ranging from 5.4 to 13.9%, and were concentration-independent.","Development and validation of a gas chromatography-mass spectrometry method for the simultaneous determination of buprenorphine, flunitrazepam and their metabolites in rat plasma: application to the pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15203048/),%,81,27619,DB01544,Flunitrazepam
,15203048,Recoveries,"Recoveries were 71, 67 and 81%, for BUP, FNZ and N-DMFNZ, respectively, and 51% for NBUP and 7-AFNZ, with CV ranging from 5.4 to 13.9%, and were concentration-independent.","Development and validation of a gas chromatography-mass spectrometry method for the simultaneous determination of buprenorphine, flunitrazepam and their metabolites in rat plasma: application to the pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15203048/),%,51,27620,DB01544,Flunitrazepam
,15701774,occupancy,The mACh receptor occupancy was estimated to be decreased from 0.22% to 0.020% by replacing paroxetine with fluvoxamine.,Improvement of dry mouth by replacing paroxetine with fluvoxamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15701774/),%,0.22,29064,DB01544,Flunitrazepam
,15701774,occupancy,The mACh receptor occupancy was estimated to be decreased from 0.22% to 0.020% by replacing paroxetine with fluvoxamine.,Improvement of dry mouth by replacing paroxetine with fluvoxamine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15701774/),%,0.020,29065,DB01544,Flunitrazepam
,3919752,elimination half-life,The rapid elimination of the antagonist could be characterized by an elimination half-life between 0.9 to 1.4 h and a total plasma clearance of 727 to 1440 ml/min.,Flunitrazepam and lormetazepam do not affect the pharmacokinetics of the benzodiazepine antagonist Ro 15-1788. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919752/),h,0.9 to 1.4,36181,DB01544,Flunitrazepam
,3919752,total plasma clearance,The rapid elimination of the antagonist could be characterized by an elimination half-life between 0.9 to 1.4 h and a total plasma clearance of 727 to 1440 ml/min.,Flunitrazepam and lormetazepam do not affect the pharmacokinetics of the benzodiazepine antagonist Ro 15-1788. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3919752/),[ml] / [min],727 to 1440,36182,DB01544,Flunitrazepam
,15917146,distribution half-life,"Plasma buprenorphine kinetics was well described by a three-compartment linear model, with a distribution half-life of 7.4+/-2.7 min and an elimination half-life of 463.9+/-152.3 min.",Flunitrazepam does not alter cerebral distribution of buprenorphine in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917146/),min,7.4,50703,DB01544,Flunitrazepam
,15917146,elimination half-life,"Plasma buprenorphine kinetics was well described by a three-compartment linear model, with a distribution half-life of 7.4+/-2.7 min and an elimination half-life of 463.9+/-152.3 min.",Flunitrazepam does not alter cerebral distribution of buprenorphine in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917146/),min,463.9,50704,DB01544,Flunitrazepam
,27861318,plasma trough concentration,"It has been suggested that a plasma trough concentration of aripiprazole plus its active metabolite, dehydroaripiprazole of 225 ng/mL is a threshold for a good therapeutic response in the treatment of acutely exacerbated patients with schizophrenia.",Prediction of an Optimal Dose of Aripiprazole in the Treatment of Schizophrenia From Plasma Concentrations of Aripiprazole Plus Its Active Metabolite Dehydroaripiprazole at Week 1. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27861318/),[ng] / [ml],225,52271,DB01544,Flunitrazepam
,6743452,half-life,Flunitrazepam has a faster and more extensive tissue distribution and a more rapid elimination (half-life about 12 h) in children than in adults.,Flunitrazepam as an induction agent in children. A clinical and pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6743452/),h,12,58425,DB01544,Flunitrazepam
,4048249,bioavailability,"The i.v. kinetics is biexponential and the g.i. absorption is very rapid (with a plasma peak at 0.25 hour) with a good bioavailability (69%); the apparent distribution volume is high, 4.8 L/kg; the half-life is equal to 3.5 hours; the elimination constant is equal to 0.8 h-1; the urinary excretion of FNZ-equivalent is negligible; the plasma total clearance is equal to 3.9 (L/kg)h-1.",Pharmacokinetics of flunitrazepam in rats studied by a radioreceptor assay. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4048249/),%,69,72076,DB01544,Flunitrazepam
,4048249,apparent distribution volume,"The i.v. kinetics is biexponential and the g.i. absorption is very rapid (with a plasma peak at 0.25 hour) with a good bioavailability (69%); the apparent distribution volume is high, 4.8 L/kg; the half-life is equal to 3.5 hours; the elimination constant is equal to 0.8 h-1; the urinary excretion of FNZ-equivalent is negligible; the plasma total clearance is equal to 3.9 (L/kg)h-1.",Pharmacokinetics of flunitrazepam in rats studied by a radioreceptor assay. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4048249/),[l] / [kg],4.8,72077,DB01544,Flunitrazepam
,4048249,half-life,"The i.v. kinetics is biexponential and the g.i. absorption is very rapid (with a plasma peak at 0.25 hour) with a good bioavailability (69%); the apparent distribution volume is high, 4.8 L/kg; the half-life is equal to 3.5 hours; the elimination constant is equal to 0.8 h-1; the urinary excretion of FNZ-equivalent is negligible; the plasma total clearance is equal to 3.9 (L/kg)h-1.",Pharmacokinetics of flunitrazepam in rats studied by a radioreceptor assay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4048249/),h,3.5,72078,DB01544,Flunitrazepam
,4048249,elimination constant,"The i.v. kinetics is biexponential and the g.i. absorption is very rapid (with a plasma peak at 0.25 hour) with a good bioavailability (69%); the apparent distribution volume is high, 4.8 L/kg; the half-life is equal to 3.5 hours; the elimination constant is equal to 0.8 h-1; the urinary excretion of FNZ-equivalent is negligible; the plasma total clearance is equal to 3.9 (L/kg)h-1.",Pharmacokinetics of flunitrazepam in rats studied by a radioreceptor assay. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4048249/),1/[h],0.8,72079,DB01544,Flunitrazepam
,4048249,plasma total clearance,"The i.v. kinetics is biexponential and the g.i. absorption is very rapid (with a plasma peak at 0.25 hour) with a good bioavailability (69%); the apparent distribution volume is high, 4.8 L/kg; the half-life is equal to 3.5 hours; the elimination constant is equal to 0.8 h-1; the urinary excretion of FNZ-equivalent is negligible; the plasma total clearance is equal to 3.9 (L/kg)h-1.",Pharmacokinetics of flunitrazepam in rats studied by a radioreceptor assay. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4048249/),[l] / [kg)h],3.9,72080,DB01544,Flunitrazepam
,6121579,peak plasma levels,"4 Mean peak plasma levels of lormetazepam binding equivalents were 4.8 +/- 1 ng/ml at 2 h after lormetazepam, 7.2 +/- 1.8 ng/ml at 8 h after flunitrazepam, and 17.9 +/- 2.7 ng/ml at 15 h after diazepam.",A radioreceptor assay to study the affinity of benzodiazepines and their receptor binding activity in human plasma including their active metabolites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121579/),[ng] / [ml],4.8,77646,DB01544,Flunitrazepam
,6121579,peak plasma levels,"4 Mean peak plasma levels of lormetazepam binding equivalents were 4.8 +/- 1 ng/ml at 2 h after lormetazepam, 7.2 +/- 1.8 ng/ml at 8 h after flunitrazepam, and 17.9 +/- 2.7 ng/ml at 15 h after diazepam.",A radioreceptor assay to study the affinity of benzodiazepines and their receptor binding activity in human plasma including their active metabolites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121579/),[ng] / [ml],7.2,77647,DB01544,Flunitrazepam
,6121579,peak plasma levels,"4 Mean peak plasma levels of lormetazepam binding equivalents were 4.8 +/- 1 ng/ml at 2 h after lormetazepam, 7.2 +/- 1.8 ng/ml at 8 h after flunitrazepam, and 17.9 +/- 2.7 ng/ml at 15 h after diazepam.",A radioreceptor assay to study the affinity of benzodiazepines and their receptor binding activity in human plasma including their active metabolites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121579/),[ng] / [ml],17.9,77648,DB01544,Flunitrazepam
,6121579,Plasma elimination half-lives,"Plasma elimination half-lives of benzodiazepine binding equivalents were 9.3, 23 and 63 h, respectively.",A radioreceptor assay to study the affinity of benzodiazepines and their receptor binding activity in human plasma including their active metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121579/),h,9.3,77649,DB01544,Flunitrazepam
,6121579,Plasma elimination half-lives,"Plasma elimination half-lives of benzodiazepine binding equivalents were 9.3, 23 and 63 h, respectively.",A radioreceptor assay to study the affinity of benzodiazepines and their receptor binding activity in human plasma including their active metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121579/),h,23,77650,DB01544,Flunitrazepam
,6121579,Plasma elimination half-lives,"Plasma elimination half-lives of benzodiazepine binding equivalents were 9.3, 23 and 63 h, respectively.",A radioreceptor assay to study the affinity of benzodiazepines and their receptor binding activity in human plasma including their active metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121579/),h,63,77651,DB01544,Flunitrazepam
,6130046,Vd1,"The mean distribution volumes of flunitrazepam, calculated by the three-compartment open model, were Vd1 0.61 (SD = 0.36) l/kg, Vd2 1.4 (SD = 0.70) l/kg, and Vd3 3.6 (SD = 1.39) l/kg.",A pharmacokinetic and pharmacodynamic study of flunitrazepam. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6130046/),[l] / [kg],0.61,79513,DB01544,Flunitrazepam
,6130046,Vd2,"The mean distribution volumes of flunitrazepam, calculated by the three-compartment open model, were Vd1 0.61 (SD = 0.36) l/kg, Vd2 1.4 (SD = 0.70) l/kg, and Vd3 3.6 (SD = 1.39) l/kg.",A pharmacokinetic and pharmacodynamic study of flunitrazepam. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6130046/),[l] / [kg],1.4,79514,DB01544,Flunitrazepam
,6130046,Vd3,"The mean distribution volumes of flunitrazepam, calculated by the three-compartment open model, were Vd1 0.61 (SD = 0.36) l/kg, Vd2 1.4 (SD = 0.70) l/kg, and Vd3 3.6 (SD = 1.39) l/kg.",A pharmacokinetic and pharmacodynamic study of flunitrazepam. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6130046/),[l] / [kg],3.6,79515,DB01544,Flunitrazepam
,6130046,elimination half-life,The mean elimination half-life was 25 h and serum clearance was 94 ml/min.,A pharmacokinetic and pharmacodynamic study of flunitrazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6130046/),h,25,79516,DB01544,Flunitrazepam
,6130046,serum clearance,The mean elimination half-life was 25 h and serum clearance was 94 ml/min.,A pharmacokinetic and pharmacodynamic study of flunitrazepam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6130046/),[ml] / [min],94,79517,DB01544,Flunitrazepam
,6664823,relative affinity,The relative affinity of the 1-hydroxymethyl and 4-hydroxy metabolites of brotizolam and midazolam were 0.33 and 0.14 respectively for brotizolam and 0.64 and 0.23 for midazolam.,Assay of midazolam and brotizolam in plasma by a gas chromatographic and a radioreceptor technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6664823/),,0.33,80465,DB01544,Flunitrazepam
,6664823,relative affinity,The relative affinity of the 1-hydroxymethyl and 4-hydroxy metabolites of brotizolam and midazolam were 0.33 and 0.14 respectively for brotizolam and 0.64 and 0.23 for midazolam.,Assay of midazolam and brotizolam in plasma by a gas chromatographic and a radioreceptor technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6664823/),,0.14,80466,DB01544,Flunitrazepam
,6664823,relative affinity,The relative affinity of the 1-hydroxymethyl and 4-hydroxy metabolites of brotizolam and midazolam were 0.33 and 0.14 respectively for brotizolam and 0.64 and 0.23 for midazolam.,Assay of midazolam and brotizolam in plasma by a gas chromatographic and a radioreceptor technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6664823/),,0.64,80467,DB01544,Flunitrazepam
,6664823,relative affinity,The relative affinity of the 1-hydroxymethyl and 4-hydroxy metabolites of brotizolam and midazolam were 0.33 and 0.14 respectively for brotizolam and 0.64 and 0.23 for midazolam.,Assay of midazolam and brotizolam in plasma by a gas chromatographic and a radioreceptor technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6664823/),,0.23,80468,DB01544,Flunitrazepam
,2874007,half-life,"As loprazolam has a half-life of 7 to 8 hours in healthy adults it may have advantages over longer-acting hypnotics, particularly when residual sedative effects on the day after ingestion are undesirable, although at doses greater than 1 mg residual sedation may occur.",Loprazolam. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in insomnia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2874007/),h,7 to 8,84334,DB01544,Flunitrazepam
,2096104,oral clearance,"Pharmacokinetic parameters did not differ significantly between healthy subjects and liver disease patients: the oral clearance was 3.5 +/- 0.8, 3.5 +/- 1.9 and 4.0 +/- 1.2 ml/min/kg, respectively in healthy subjects, patients with hepatitis and patients with cirrhosis.",Pharmacokinetics of flunitrazepam following single dose oral administration in liver disease patients compared with healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2096104/),[ml] / [kg·min],3.5,95745,DB01544,Flunitrazepam
,2096104,oral clearance,"Pharmacokinetic parameters did not differ significantly between healthy subjects and liver disease patients: the oral clearance was 3.5 +/- 0.8, 3.5 +/- 1.9 and 4.0 +/- 1.2 ml/min/kg, respectively in healthy subjects, patients with hepatitis and patients with cirrhosis.",Pharmacokinetics of flunitrazepam following single dose oral administration in liver disease patients compared with healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2096104/),[ml] / [kg·min],3.5,95746,DB01544,Flunitrazepam
,2096104,oral clearance,"Pharmacokinetic parameters did not differ significantly between healthy subjects and liver disease patients: the oral clearance was 3.5 +/- 0.8, 3.5 +/- 1.9 and 4.0 +/- 1.2 ml/min/kg, respectively in healthy subjects, patients with hepatitis and patients with cirrhosis.",Pharmacokinetics of flunitrazepam following single dose oral administration in liver disease patients compared with healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2096104/),[ml] / [kg·min],4.0,95747,DB01544,Flunitrazepam
,2096104,apparent elimination half-life,"The apparent elimination half-life was 22 +/- 5 h in healthy subjects, 25 +/- 10 h in patients with hepatitis and 20 +/- 6 h in patients with cirrhosis.",Pharmacokinetics of flunitrazepam following single dose oral administration in liver disease patients compared with healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2096104/),h,22,95748,DB01544,Flunitrazepam
,2096104,apparent elimination half-life,"The apparent elimination half-life was 22 +/- 5 h in healthy subjects, 25 +/- 10 h in patients with hepatitis and 20 +/- 6 h in patients with cirrhosis.",Pharmacokinetics of flunitrazepam following single dose oral administration in liver disease patients compared with healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2096104/),h,25,95749,DB01544,Flunitrazepam
,2096104,apparent elimination half-life,"The apparent elimination half-life was 22 +/- 5 h in healthy subjects, 25 +/- 10 h in patients with hepatitis and 20 +/- 6 h in patients with cirrhosis.",Pharmacokinetics of flunitrazepam following single dose oral administration in liver disease patients compared with healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2096104/),h,20,95750,DB01544,Flunitrazepam
,29954,hepatic blood clearance,"Assuming the liver to be the sole eliminating organ, hepatic blood clearance and extraction ratio were approximately 0.235 liter/hr/kg and 0.154, respectively.",Pharmacokinetics of flunitrazepam following single- and multiple-dose oral administration to healthy human subjects. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29954/),[l] / [h·kg],0.235,113465,DB01544,Flunitrazepam
,29954,extraction ratio,"Assuming the liver to be the sole eliminating organ, hepatic blood clearance and extraction ratio were approximately 0.235 liter/hr/kg and 0.154, respectively.",Pharmacokinetics of flunitrazepam following single- and multiple-dose oral administration to healthy human subjects. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29954/),,0.154,113466,DB01544,Flunitrazepam
,29954,Steady-state blood volume of distribution,Steady-state blood volume of distribution averaged 3.76 liters/kg in the single-dose studies.,Pharmacokinetics of flunitrazepam following single- and multiple-dose oral administration to healthy human subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29954/),[l] / [kg],3.76,113467,DB01544,Flunitrazepam
,29954,half-lives,"Terminal exponential half-lives from the single- and multiple-dose studies (different subjects) averaged 13.5 and 19.2 hr, respectively; these differences were not due to clearance changes but were entirely attributable to variations in volumes of distribution.",Pharmacokinetics of flunitrazepam following single- and multiple-dose oral administration to healthy human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29954/),h,13.5,113468,DB01544,Flunitrazepam
,29954,half-lives,"Terminal exponential half-lives from the single- and multiple-dose studies (different subjects) averaged 13.5 and 19.2 hr, respectively; these differences were not due to clearance changes but were entirely attributable to variations in volumes of distribution.",Pharmacokinetics of flunitrazepam following single- and multiple-dose oral administration to healthy human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29954/),h,19.2,113469,DB01544,Flunitrazepam
,15902980,m,"Ions designated for TMS-derivatized alpha-hydroxytriazolam and alpha-hydroxytriazolam-d4 are m/z 415, 417, and 430 and 419, 421, and 434, respectively.",Urinary excretion of alpha-hydroxytriazolam following a single dose of halcion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15902980/),,415,135321,DB01544,Flunitrazepam
,15902980,m,"Ions designated for TMS-derivatized alpha-hydroxytriazolam and alpha-hydroxytriazolam-d4 are m/z 415, 417, and 430 and 419, 421, and 434, respectively.",Urinary excretion of alpha-hydroxytriazolam following a single dose of halcion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15902980/),,417,135322,DB01544,Flunitrazepam
,15902980,m,"Ions designated for TMS-derivatized alpha-hydroxytriazolam and alpha-hydroxytriazolam-d4 are m/z 415, 417, and 430 and 419, 421, and 434, respectively.",Urinary excretion of alpha-hydroxytriazolam following a single dose of halcion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15902980/),,430,135323,DB01544,Flunitrazepam
,15902980,m,"Ions designated for TMS-derivatized alpha-hydroxytriazolam and alpha-hydroxytriazolam-d4 are m/z 415, 417, and 430 and 419, 421, and 434, respectively.",Urinary excretion of alpha-hydroxytriazolam following a single dose of halcion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15902980/),,419,135324,DB01544,Flunitrazepam
,15902980,m,"Ions designated for TMS-derivatized alpha-hydroxytriazolam and alpha-hydroxytriazolam-d4 are m/z 415, 417, and 430 and 419, 421, and 434, respectively.",Urinary excretion of alpha-hydroxytriazolam following a single dose of halcion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15902980/),,421,135325,DB01544,Flunitrazepam
,15902980,m,"Ions designated for TMS-derivatized alpha-hydroxytriazolam and alpha-hydroxytriazolam-d4 are m/z 415, 417, and 430 and 419, 421, and 434, respectively.",Urinary excretion of alpha-hydroxytriazolam following a single dose of halcion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15902980/),,434,135326,DB01544,Flunitrazepam
,15902980,recovery,"The overall protocol achieved the following results when applied to the analysis of 2-mL drug-free urine specimens fortified with 10-200 ng/mL alpha-hydroxytriazolam: recovery, 95%; interday and intraday precision ranges, 1.50-3.52% and 0.93-4.71%, respectively; linearity, r2 > 0.99; and limits of detection and quantitation, 0.05 and 0.1 ng/mL, respectively.",Urinary excretion of alpha-hydroxytriazolam following a single dose of halcion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15902980/),%,95,135327,DB01544,Flunitrazepam
,6102520,Maximal plasma concentrations,"Maximal plasma concentrations of unchanged flunitrazepam, found two hours after intake, reached 10-15 ng/ml after the first and 15-20 ng/ml after the last dose.",Pharmacokinetic and clinical observations on prolonged administration of flunitrazepam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6102520/),[ng] / [ml],10-15,150606,DB01544,Flunitrazepam
,6102520,Maximal plasma concentrations,"Maximal plasma concentrations of unchanged flunitrazepam, found two hours after intake, reached 10-15 ng/ml after the first and 15-20 ng/ml after the last dose.",Pharmacokinetic and clinical observations on prolonged administration of flunitrazepam. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6102520/),[ng] / [ml],15-20,150607,DB01544,Flunitrazepam
,6102520,beta-half-life,The beta-half-life was found to be between 20 and 36 h.,Pharmacokinetic and clinical observations on prolonged administration of flunitrazepam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6102520/),h,20 and 36,150608,DB01544,Flunitrazepam
,2820763,IC50,"In vitro, tabernanthine inhibited specific flunitrazepam binding in a competitive manner with an affinity (IC50 150 microM) in the same range as harmane.",Benzodiazepine receptors are involved in tabernanthine-induced tremor: in vitro and in vivo evidence. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2820763/),μM,150,155188,DB01544,Flunitrazepam
,2820763,half-life,"In vivo, the time course of tremorigenic activity was related to the tabernanthine concentration in brain (half-life = 2 h).",Benzodiazepine receptors are involved in tabernanthine-induced tremor: in vitro and in vivo evidence. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2820763/),h,2,155189,DB01544,Flunitrazepam
,9536021,IC50,Triazolam alone inhibited [3H]flunitrazepam binding with an IC50 value of 0.85 nM and a Ki value of 0.50 nM.,"Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536021/),nM,0.85,162462,DB01544,Flunitrazepam
,9536021,Ki,Triazolam alone inhibited [3H]flunitrazepam binding with an IC50 value of 0.85 nM and a Ki value of 0.50 nM.,"Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536021/),nM,0.50,162463,DB01544,Flunitrazepam
,9536021,IC50,Ketoconazole alone also competitively antagonized [3H]flunitrazepam binding in a concentration-dependent manner with an IC50 value of 1.56 microM and a Ki value of 1.17 microM.,"Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536021/),μM,1.56,162464,DB01544,Flunitrazepam
,9536021,Ki,Ketoconazole alone also competitively antagonized [3H]flunitrazepam binding in a concentration-dependent manner with an IC50 value of 1.56 microM and a Ki value of 1.17 microM.,"Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536021/),μM,1.17,162465,DB01544,Flunitrazepam
,9536021,IC50,"In the presence of 1, 3 or 9 microM ketoconazole, the IC50 value of triazolam was increased to 1.11, 1. 58 and 5.73 nM, respectively, whereas maximal binding was reduced by 36%, 69% and 89%.","Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536021/),nM,1.11,162466,DB01544,Flunitrazepam
,9536021,IC50,"In the presence of 1, 3 or 9 microM ketoconazole, the IC50 value of triazolam was increased to 1.11, 1. 58 and 5.73 nM, respectively, whereas maximal binding was reduced by 36%, 69% and 89%.","Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536021/),nM,1. 58,162467,DB01544,Flunitrazepam
,9536021,IC50,"In the presence of 1, 3 or 9 microM ketoconazole, the IC50 value of triazolam was increased to 1.11, 1. 58 and 5.73 nM, respectively, whereas maximal binding was reduced by 36%, 69% and 89%.","Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9536021/),nM,5.73,162468,DB01544,Flunitrazepam
,17293174,total run time,"Omeprazole and flunitrazepam, the internal standard, elute at 0.80+/-0.10 min with a total run time 1.35 min.",Rapid determination of omeprazole in human plasma by protein precipitation and liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17293174/),min,1.35,166723,DB01544,Flunitrazepam
,17293174,m/z,"Quantification was through positive ion mode and selected reaction monitoring mode at m/z 346.1-->197.9 for omeprazole and m/z 314.0-->268.0 for flunitrazepam, respectively.",Rapid determination of omeprazole in human plasma by protein precipitation and liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17293174/),,346.1,166724,DB01544,Flunitrazepam
,17293174,m/z,"Quantification was through positive ion mode and selected reaction monitoring mode at m/z 346.1-->197.9 for omeprazole and m/z 314.0-->268.0 for flunitrazepam, respectively.",Rapid determination of omeprazole in human plasma by protein precipitation and liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17293174/),,197.9,166725,DB01544,Flunitrazepam
,17293174,m/z,"Quantification was through positive ion mode and selected reaction monitoring mode at m/z 346.1-->197.9 for omeprazole and m/z 314.0-->268.0 for flunitrazepam, respectively.",Rapid determination of omeprazole in human plasma by protein precipitation and liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17293174/),,314.0,166726,DB01544,Flunitrazepam
,17293174,m/z,"Quantification was through positive ion mode and selected reaction monitoring mode at m/z 346.1-->197.9 for omeprazole and m/z 314.0-->268.0 for flunitrazepam, respectively.",Rapid determination of omeprazole in human plasma by protein precipitation and liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17293174/),,268.0,166727,DB01544,Flunitrazepam
,2874974,half-life,"Minimal impairment of psychomotor skills and mental acuity occurs in the morning after a bedtime dose of zopiclone, which has a short half-life of about 5 hours and no long acting metabolites.",Zopiclone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2874974/),h,5,173477,DB01544,Flunitrazepam
,2015176,plasma drug concentration producing 50% of maximal effect (EC50),"The plasma drug concentration producing 50% of maximal effect (EC50) was found to be 7.0 and 6.5 ng ml-1 on the two occasions, respectively.",Inter- and intraindividual variability in the concentration-effect (sedation) relationship of flunitrazepam. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015176/),[ng] / [ml],7.0,175490,DB01544,Flunitrazepam
,2015176,plasma drug concentration producing 50% of maximal effect (EC50),"The plasma drug concentration producing 50% of maximal effect (EC50) was found to be 7.0 and 6.5 ng ml-1 on the two occasions, respectively.",Inter- and intraindividual variability in the concentration-effect (sedation) relationship of flunitrazepam. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015176/),[ng] / [ml],6.5,175491,DB01544,Flunitrazepam
,2015176,s,3. The steepness of the concentration-response curve as reflected in the slope factor(s) showed a virtual 'all or none' response to flunitrazepam with s values ranging from 3 to 30 with a mean of about 14.,Inter- and intraindividual variability in the concentration-effect (sedation) relationship of flunitrazepam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015176/),,3 to 30,175492,DB01544,Flunitrazepam
,2842128,absorption half-life,"Following oral administration, flumazenil is absorbed rapidly (peak concentrations are achieved after 20-90 min absorption half-life 0.3 h) but bio-availability is low (16%) owing to significant pre-systemic elimination.",Drug interactions and clinical pharmacokinetics of flumazenil. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),min,20-90,206677,DB01544,Flunitrazepam
,2842128,absorption half-life,"Following oral administration, flumazenil is absorbed rapidly (peak concentrations are achieved after 20-90 min absorption half-life 0.3 h) but bio-availability is low (16%) owing to significant pre-systemic elimination.",Drug interactions and clinical pharmacokinetics of flumazenil. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),h,0.3,206678,DB01544,Flunitrazepam
,2842128,bio-availability,"Following oral administration, flumazenil is absorbed rapidly (peak concentrations are achieved after 20-90 min absorption half-life 0.3 h) but bio-availability is low (16%) owing to significant pre-systemic elimination.",Drug interactions and clinical pharmacokinetics of flumazenil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),%,16,206679,DB01544,Flunitrazepam
,2842128,half-life,"This can be characterized either by the short half-life of 0.7-1.3 h or, better, by the high plasma and blood clearance of 520-1300 ml min-1.",Drug interactions and clinical pharmacokinetics of flumazenil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),h,0.7-1.3,206680,DB01544,Flunitrazepam
,2842128,plasma,"This can be characterized either by the short half-life of 0.7-1.3 h or, better, by the high plasma and blood clearance of 520-1300 ml min-1.",Drug interactions and clinical pharmacokinetics of flumazenil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),[ml] / [min],520-1300,206681,DB01544,Flunitrazepam
,2842128,blood clearance,"This can be characterized either by the short half-life of 0.7-1.3 h or, better, by the high plasma and blood clearance of 520-1300 ml min-1.",Drug interactions and clinical pharmacokinetics of flumazenil. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),[ml] / [min],520-1300,206682,DB01544,Flunitrazepam
,2842128,plasma protein binding,The low plasma protein binding of flumazenil (about 40%) will not limit its wide distribution (apparent distribution volume 0.6-1 kg) or its partly flow-dependent hepatic elimination.,Drug interactions and clinical pharmacokinetics of flumazenil. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),%,40,206683,DB01544,Flunitrazepam
,2842128,apparent distribution volume,The low plasma protein binding of flumazenil (about 40%) will not limit its wide distribution (apparent distribution volume 0.6-1 kg) or its partly flow-dependent hepatic elimination.,Drug interactions and clinical pharmacokinetics of flumazenil. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2842128/),kg,0.6-1,206684,DB01544,Flunitrazepam
,3281819,elimination half-life,"Brotizolam has an elimination half-life of about 5 hours, which is 'intermediate' compared with the shorter-acting hypnotic, triazolam, and longer-acting benzodiazepines.","Brotizolam. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an hypnotic. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3281819/),h,5,208420,DB01544,Flunitrazepam
,10460067,half-life,"After the single dose (n = 28), half-life was 22.6 +/- 7.3 hours, clearance was 0.15 +/- 0.14 L x kg x h(-1), and volume of distribution was 4.6 +/- 4.1 L x kg(-1) (mean +/- SD).",Pharmacokinetics and tolerance of flunitrazepam in neonates and in infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460067/),h,22.6,208440,DB01544,Flunitrazepam
,10460067,clearance,"After the single dose (n = 28), half-life was 22.6 +/- 7.3 hours, clearance was 0.15 +/- 0.14 L x kg x h(-1), and volume of distribution was 4.6 +/- 4.1 L x kg(-1) (mean +/- SD).",Pharmacokinetics and tolerance of flunitrazepam in neonates and in infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460067/),[kg·l] / [h],0.15,208441,DB01544,Flunitrazepam
,10460067,volume of distribution,"After the single dose (n = 28), half-life was 22.6 +/- 7.3 hours, clearance was 0.15 +/- 0.14 L x kg x h(-1), and volume of distribution was 4.6 +/- 4.1 L x kg(-1) (mean +/- SD).",Pharmacokinetics and tolerance of flunitrazepam in neonates and in infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460067/),[l] / [kg],4.6,208442,DB01544,Flunitrazepam
,6114680,biological halflives,"Diazepam, flunitrazepam and midazolam have different pharmacokinetic properties, their biological halflives for instance, being 24 to 48 hours, 4,5 hours and 2,5 hours respectively.","[Clinical pharmacokinetics of midazolam, flunitrazepam and diazepam (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114680/),h,24 to 48,209320,DB01544,Flunitrazepam
,6114680,biological halflives,"Diazepam, flunitrazepam and midazolam have different pharmacokinetic properties, their biological halflives for instance, being 24 to 48 hours, 4,5 hours and 2,5 hours respectively.","[Clinical pharmacokinetics of midazolam, flunitrazepam and diazepam (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114680/),h,"4,5",209321,DB01544,Flunitrazepam
,6114680,biological halflives,"Diazepam, flunitrazepam and midazolam have different pharmacokinetic properties, their biological halflives for instance, being 24 to 48 hours, 4,5 hours and 2,5 hours respectively.","[Clinical pharmacokinetics of midazolam, flunitrazepam and diazepam (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114680/),h,"2,5",209322,DB01544,Flunitrazepam
,6114680,total plasma clearances,"Moreover, the total plasma clearances calculated for these drugs resulted in 30 ml/min for diazepam, 250 ml/min for flunitrazepam and 450 ml/min for midazolam.","[Clinical pharmacokinetics of midazolam, flunitrazepam and diazepam (author's transl)]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114680/),[ml] / [min],30,209323,DB01544,Flunitrazepam
,6114680,total plasma clearances,"Moreover, the total plasma clearances calculated for these drugs resulted in 30 ml/min for diazepam, 250 ml/min for flunitrazepam and 450 ml/min for midazolam.","[Clinical pharmacokinetics of midazolam, flunitrazepam and diazepam (author's transl)]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114680/),[ml] / [min],250,209324,DB01544,Flunitrazepam
,6114680,total plasma clearances,"Moreover, the total plasma clearances calculated for these drugs resulted in 30 ml/min for diazepam, 250 ml/min for flunitrazepam and 450 ml/min for midazolam.","[Clinical pharmacokinetics of midazolam, flunitrazepam and diazepam (author's transl)]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114680/),[ml] / [min],450,209325,DB01544,Flunitrazepam
,6114680,V1,"On the other hand, all three drugs were found to have nearly the same volumes of distribution (V1: 25 l, VdSS: 80-100 l).","[Clinical pharmacokinetics of midazolam, flunitrazepam and diazepam (author's transl)]. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114680/),l,25,209326,DB01544,Flunitrazepam
,6114680,VdSS,"On the other hand, all three drugs were found to have nearly the same volumes of distribution (V1: 25 l, VdSS: 80-100 l).","[Clinical pharmacokinetics of midazolam, flunitrazepam and diazepam (author's transl)]. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114680/),l,80-100,209327,DB01544,Flunitrazepam
,6114680,biological halflife,"Of the 3 benzodiazepines investigated, diazepam reveals extremely complex pharmacokinetic effects which vary the duration of pharmacological responses very widely; besides drug interaction, enzyme induction and -inhibition it gives rise to the active metabolite N-desmethyl-diazepam (biological halflife 50 to 120 hours).","[Clinical pharmacokinetics of midazolam, flunitrazepam and diazepam (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6114680/),h,50 to 120,209328,DB01544,Flunitrazepam
,12742689,ICRs,The ICRs ranged from 0.002 (flunitrazepam) to 0.049 (flurazepam).,A study into the rate of incorporation of eight benzodiazepines into rat hair. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742689/),,0.002,222417,DB01544,Flunitrazepam
,12742689,ICRs,The ICRs ranged from 0.002 (flunitrazepam) to 0.049 (flurazepam).,A study into the rate of incorporation of eight benzodiazepines into rat hair. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12742689/),,0.049,222418,DB01544,Flunitrazepam
,7582385,peak plasma level (Cmax),"The mean +/- SD kinetic parameters were: peak plasma level (Cmax) 607 +/- 231 micrograms.l-1 reached in 1.93 +/- 1.39 h (tmax), elimination half-life (t1/2) 5.55 +/- 0.98 h, area under the plasma concentration time curve (AUC0-infinity) 4,772.1 +/- 1,318.4 micrograms.",Pharmacokinetics of cetirizine in 2- to 6-year-old children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582385/),[μg] / [l],607,261207,DB01544,Flunitrazepam
,7582385,tmax,"The mean +/- SD kinetic parameters were: peak plasma level (Cmax) 607 +/- 231 micrograms.l-1 reached in 1.93 +/- 1.39 h (tmax), elimination half-life (t1/2) 5.55 +/- 0.98 h, area under the plasma concentration time curve (AUC0-infinity) 4,772.1 +/- 1,318.4 micrograms.",Pharmacokinetics of cetirizine in 2- to 6-year-old children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582385/),h,1.93,261208,DB01544,Flunitrazepam
,7582385,elimination half-life (t1/2),"The mean +/- SD kinetic parameters were: peak plasma level (Cmax) 607 +/- 231 micrograms.l-1 reached in 1.93 +/- 1.39 h (tmax), elimination half-life (t1/2) 5.55 +/- 0.98 h, area under the plasma concentration time curve (AUC0-infinity) 4,772.1 +/- 1,318.4 micrograms.",Pharmacokinetics of cetirizine in 2- to 6-year-old children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582385/),h,5.55,261209,DB01544,Flunitrazepam
,7582385,area under the plasma concentration time curve (AUC0-infinity),"The mean +/- SD kinetic parameters were: peak plasma level (Cmax) 607 +/- 231 micrograms.l-1 reached in 1.93 +/- 1.39 h (tmax), elimination half-life (t1/2) 5.55 +/- 0.98 h, area under the plasma concentration time curve (AUC0-infinity) 4,772.1 +/- 1,318.4 micrograms.",Pharmacokinetics of cetirizine in 2- to 6-year-old children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582385/),μg,"4,772.1",261210,DB01544,Flunitrazepam
,7582385,mean residence time (MRT),"l-1.h, mean residence time (MRT) 8.13 +/- 1.31 h, apparent plasma clearance (Cl/f) 1.27 +/- 0.80 ml.min-1.kg-1, apparent volume of distribution (Vz/f) 0.60 +/- 0.38 l.kg-1.",Pharmacokinetics of cetirizine in 2- to 6-year-old children. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582385/),h,8.13,261211,DB01544,Flunitrazepam
,7582385,apparent plasma clearance (Cl/f),"l-1.h, mean residence time (MRT) 8.13 +/- 1.31 h, apparent plasma clearance (Cl/f) 1.27 +/- 0.80 ml.min-1.kg-1, apparent volume of distribution (Vz/f) 0.60 +/- 0.38 l.kg-1.",Pharmacokinetics of cetirizine in 2- to 6-year-old children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582385/),[ml] / [kg·min],1.27,261212,DB01544,Flunitrazepam
,7582385,apparent volume of distribution (Vz/f),"l-1.h, mean residence time (MRT) 8.13 +/- 1.31 h, apparent plasma clearance (Cl/f) 1.27 +/- 0.80 ml.min-1.kg-1, apparent volume of distribution (Vz/f) 0.60 +/- 0.38 l.kg-1.",Pharmacokinetics of cetirizine in 2- to 6-year-old children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582385/),[l] / [kg],0.60,261213,DB01544,Flunitrazepam
,7582385,Urinary recovery,Urinary recovery was 38.4 +/- 9.9% (n = 4) of the dose.,Pharmacokinetics of cetirizine in 2- to 6-year-old children. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582385/),%,38.4,261214,DB01544,Flunitrazepam
,7582385,Renal clearance,Renal clearance was 0.42 +/- 0.10 ml.min-1.kg-1 (n = 6).,Pharmacokinetics of cetirizine in 2- to 6-year-old children. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7582385/),[ml] / [kg·min],0.42,261215,DB01544,Flunitrazepam
,23801,bioavailability,For flunitrazepam suppositories the bioavailability was found to be about 50%.,Bioavailability from various galenic formulations of flunitrazepam. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23801/),%,50,265954,DB01544,Flunitrazepam
,3512140,elimination half-life,Its elimination half-life is 149 minutes and its clearance is 11.3 ml/min/kg.,Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,149,268206,DB01544,Flunitrazepam
,3512140,clearance,Its elimination half-life is 149 minutes and its clearance is 11.3 ml/min/kg.,Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),[ml] / [kg·min],11.3,268207,DB01544,Flunitrazepam
,3512140,elimination half-life,"Its distribution and redistribution are rapid, with an elimination half-life of 83 to 137 minutes and a clearance of 4.37 to 6.47 ml/min/kg in adult patients.",Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,83 to 137,268208,DB01544,Flunitrazepam
,3512140,clearance,"Its distribution and redistribution are rapid, with an elimination half-life of 83 to 137 minutes and a clearance of 4.37 to 6.47 ml/min/kg in adult patients.",Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),[ml] / [kg·min],4.37 to 6.47,268209,DB01544,Flunitrazepam
,3512140,distribution,"Etomidate, a carboxylated imidazole, is rapidly distributed within a central compartment and then to peripheral compartments; its slow distribution and terminal elimination half-lives are 28 and 273 to 330 minutes, respectively, and its clearance (11.6 to 25 ml/min/kg) is equal to its hepatic plasma flow.",Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,28,268210,DB01544,Flunitrazepam
,3512140,terminal elimination half-lives,"Etomidate, a carboxylated imidazole, is rapidly distributed within a central compartment and then to peripheral compartments; its slow distribution and terminal elimination half-lives are 28 and 273 to 330 minutes, respectively, and its clearance (11.6 to 25 ml/min/kg) is equal to its hepatic plasma flow.",Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,273 to 330,268211,DB01544,Flunitrazepam
,3512140,clearance,"Etomidate, a carboxylated imidazole, is rapidly distributed within a central compartment and then to peripheral compartments; its slow distribution and terminal elimination half-lives are 28 and 273 to 330 minutes, respectively, and its clearance (11.6 to 25 ml/min/kg) is equal to its hepatic plasma flow.",Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),[ml] / [kg·min],11.6 to 25,268212,DB01544,Flunitrazepam
,3512140,half-life,Distribution is rapid with a mean half-life of 2.1 minutes and an elimination half-life of 47 minutes.,Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,2.1,268213,DB01544,Flunitrazepam
,3512140,elimination half-life,Distribution is rapid with a mean half-life of 2.1 minutes and an elimination half-life of 47 minutes.,Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,47,268214,DB01544,Flunitrazepam
,6128350,sensitivity limit,The sensitivity limit is about 1 ng/ml of plasma for both 7-amino-flunitrazepam and 7-amino-desmethylflunitrazepam.,Determination of 7-amino-flunitrazepam (Ro 20-1815) and 7-amino-desmethylflunitrazepam (Ro 5-4650) in plasma by high-performance liquid chromatography and fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6128350/),[ng] / [ml],1,268829,DB01544,Flunitrazepam
